Regeneron Pharmaceuticals (REGN) said Wednesday that it expects Q1 net income to be negatively impacted by about $0.81 per diluted share due to an acquired in-process research and development charge of approximately $102 million on a pre-tax basis.
The charge primarily relates to premium on equity securities purchased, as well as development milestone and upfront payments under collaboration and licensing agreements, the company said in a filing with the US Securities and Exchange Commission.
Regeneron said last month that it will report its Q1 financial and operating results on April 29.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments